|
|
(One intermediate revision by the same user not shown) |
Line 20: |
Line 20: |
| <IMG class="team" src="https://static.igem.org/mediawiki/2015/d/d2/Leicester_Team_photo.JPG"> | | <IMG class="team" src="https://static.igem.org/mediawiki/2015/d/d2/Leicester_Team_photo.JPG"> |
| | | |
− | <h1 align=center>Welcome to the University of Leicester iGEM Team Page</h1> | + | <h2 align=center>Welcome to the University of Leicester iGEM Team Page</h2> |
| | | |
− | <h4>Project Abstract</h4>
| |
− | <p>Neurodegenerative disorders show decreased levels of NAD+/NAD(H). Using E. coli to colonise the gut, NAD+/NAD(H) levels could be increased by upregulating nadD, nadE and PncB enzymes in the E. coli cytosol; these gene products will be tagged and exported into the periplasm via the tat system to produce NAD+/NAD(H), which will be exported into the gut. The genes and killswitch will be inserted into E. coli, whilst the remaining aspects of the project will be theoretical due to ethical and safety restrictions. Speculatively, increased NAD+/NAD(H) could treat neurodegenerative disorders by mitigating the destruction of neurons and help with muscle fatigue. Regeneration of muscle fibres to restore strength and overall energy levels would be achieved by increased oxidative phosphorylation triggered by NAD+/NAD(H). This treatment provides low-cost NAD+/NAD(H) as part of an autonomous system; increasing the patients’ quality of life.</p>
| |
− |
| |
| | | |
| </div> | | </div> |